Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review-Reference-Cited by-同舟云学术

Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review

Published:2009-11-24 Issue:6 Volume:28 Page:887-894
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Bellati Filippo,Napoletano Chiara,Ruscito Ilary,Pastore Maria,Pernice Milena,Antonilli Morena,Nuti Marianna,Benedetti Panici Pierluigi

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-009-9351-4.pdf

Reference49 articles.

1. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96

2. Herrinton LJ, Neslund-Dudas C, Rolnick SJ et al (2007) Complications at the end of life in ovarian cancer. J Pain Symptom Manage 34:237–43

3. Ayantunde AA, Parsons SL (2007) Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 18:945–49

4. Pockros PJ, Esrason KT, Nguyen C, Duque J, Woods S (1992) Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology 103:1302–06

5. Bezwoda WR, Seymour L, Dansey R (1989) Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer. Cancer 64:1029–33

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results;Cancers;2021-06-26

2. REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer;Gynecologic Oncology;2021-05

3. Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites;Journal of International Medical Research;2021-02

4. Intraperitoneal Chemotherapy: A Strategy for the Treatment of Refractory Ascites in Recurrent Endometrial Cancer Patients – Three Case Reports and Review of the Literature;Oncology;2019-10-09

5. Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets;Journal of Clinical Medicine;2019-03-18